产品
编 号：F675300
分子式：C16H15F2N
分子量：259.29
分子式：C16H15F2N
分子量：259.29
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1266684-01-8
产品详情
生物活性：
FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities.
体内研究：
FIDAS-3 (20 mg/kg; intraperitoneal injection; daily; for one months; C57BL/6J athymic nude mice) treatment significantly inhibits the growth of xenograft tumors.Animal Model:C57BL/6J athymic nude mice (6-8 week) injected with LS174 cells
Dosage:20 mg/kg
Administration:Intraperitoneal injection; daily; for one months
Result:Significantly inhibited the growth of xenograft tumors.
体外研究：
FIDAS-3 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells. FIDAS-3 (3-10 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-3 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-3 (10 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.
FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities.
体内研究：
FIDAS-3 (20 mg/kg; intraperitoneal injection; daily; for one months; C57BL/6J athymic nude mice) treatment significantly inhibits the growth of xenograft tumors.Animal Model:C57BL/6J athymic nude mice (6-8 week) injected with LS174 cells
Dosage:20 mg/kg
Administration:Intraperitoneal injection; daily; for one months
Result:Significantly inhibited the growth of xenograft tumors.
体外研究：
FIDAS-3 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells. FIDAS-3 (3-10 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-3 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-3 (10 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备